Application No.: 10/786,094

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A method for treatment of a malignant tumor and

prevention or treatment of Graft Versus Host Disease (GVHD) induced by donor lymphocyte

infusion in a patient, the method comprising:

(A) performing donor lymphocyte infusion (DLI) in a patient having a malignant

tumor;

(B) then performing:

(i) radiation treatment (irradiation),

(ii) infusion of lymphocytes derived from the patient or derived from a third party

with an identical HLA type as the patient (HLI), and

(iii) intra bone marrow-bone marrow transplantation (IBM-BMT) using bone marrow

cells derived from the patient or derived from a third party with an identical HLA type as the

patient.

(canceled).

3. (previously presented): The method of Claim 1, wherein a first radiation

treatment is performed prior to the donor lymphocyte infusion.

2

Application No.: 10/786,094

mononuclear cells.

4. (previously presented): The method of Claim 1, wherein the DLI is performed by intravenous administration of an effective amount of donor-derived peripheral blood

- (previously presented): The method of Claim 1, wherein said radiation treatment is performed by total body irradiation at a dose of 3-4 Gy.
- 6. (previously presented): The method of Claim 1, wherein the HLI is performed by intravenous administration of an effective amount of peripheral blood mononuclear cells derived form the patient or derived from a third party with an identical HLA type as the patient.
- 7. (previously presented): The method of Claim 1, wherein the bone marrow cells are whole bone marrow cells derived from the patient or derived from a third party with an identical HLA type as the patient.
- 8. (previously presented): The method of Claim 7, wherein the whole bone marrow cells are obtained by inserting a bone marrow puncture needle into one end of a long bone of the patient or of the third party, causing an irrigating fluid to flow via the needle through the medullary cavity, and recovering the irrigating fluid containing bone marrow cells from a perforation provided at the other end of the long bone.

3

Application No.: 10/786,094

9. (previously presented): The method of Claim 1, wherein the IBM-BMT is performed by administration, into a long bone, of an effective amount of whole bone marrow cells derived from the patient or the third party.

- 10. (previously presented): A method for treatment of a malignant tumor and prevention or treatment of Graft Versus Host Disease (GVHD) induced by donor lymphocyte infusion in a patient, the method comprising:
- (A) performing donor lymphocyte infusion (DLI) in a patient having a malignant tumor; and
  - (B) then performing:
  - (i) radiation treatment (irradiation), and
- (ii) intravenous administration of peripheral blood stem cells derived from the patient or derived from a third party with an identical HLA type to the patient.
- 11. (previously presented): The method of Claim 1, wherein the malignant tumor is selected from the group consisting of leukemia, malignant lymphoma, multiple myeloma, sarcoma, melanoma, brain tumor, stomach cancer, tongue cancer, esophageal carcinoma, colorectal cancer, liver cancer, gallbladder carcinoma, pancreatic carcinoma, renal carcinoma, bladder cancer, nasopharyngeal cancer, laryngeal cancer, skin cancer, mammary cancer, testicular cancer, ovarian cancer, uterus carcinoma, and lung cancer.

## 12. (canceled).

Application No.: 10/786,094

13. (previously presented): A method for prevention or treatment of a graft versus host disease induced by donor lymphocyte infusion in a patient, the method comprising

performing, in said patient:

(A) radiation treatment (irradiation),

(B) infusion of lymphocytes derived from the patient or derived from a third party with

an identical HLA type as the patient, and

(C) intra bone marrow-bone marrow transplantation using bone marrow cells derived

from the patient or derived from a third party with an identical HLA type as the

patient,

wherein the method prevents or treats graft versus host disease induced by donor lymphocyte

infusion in the patient.

14. (canceled).

5